Biogen exits biosimilar JV with Samsung, raising $2.3bn | pharmaphorum
Samsung Bioepis begins late stage clinical trial of ustekinumab biosimilar
Samsung Bioepis says its trastuzumab biosimilar as safe, effective as original
Samsung Bioepis - Crunchbase Company Profile & Funding
Biogen to sell equity stake in Samsung Bioepis joint venture for up to $2.3B - Drug Discovery and Development
Samsung Bioepis launches Ontruzant in Brazil
Samsung Biologics acquires Samsung Bioepis joint venture for $2.3bn
Biogen launches first US biosimilar with Samsung Bioepis
Samsung Bioepis | LinkedIn
Un medicament biosimilar al Enbrel dezvoltat de Samsung Bioepis a fost aprobat în SUA - 360medical.ro
Samsung Biologics buys Biogen's stake in Samsung Bioepis for $2.3B | BioWorld
Samsung Bioepis starts selling Byooviz in U.S.
Samsung Bioepis' Ophthalmology Biosimilar Candidate Receives Clinical Approvals in 8 Markets | Be Korea-savvy
Samsung Biologics - Wikipedia
iF Design - Samsung Bioepis
Samsung Bioepis Wins Approval to Sell Biosimilar in South Korea | Be Korea-savvy
Biogen to sell equity stake in Samsung Bioepis joint venture for up to $2.3B - Drug Discovery and Development
Samsung Biologics Completes Purchase Of Samsung Bioepis | Contract Pharma
Samsung Bioepis Racks Up More Awards for Its Biosimilar Packaging
SAMSUNG BIOEPIS
Samsung Bioepis' Ranibizumab Biosimilar Application Filed With FDA
Samsung Biologics: Inclusion of Samsung Bioepis to Boost Earnings - Businesskorea
Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars Into Hong Kong and Taiwan
PharmaBoardroom - Samsung Bioepis
Samsung Biologics Acquires Full Ownership Of Samsung Bioepis | Contract Pharma
